Alexander I. Spira, MD, PhD, FACP, on Necessary Next Steps for Research in KRAS G12C+ NSCLC

Article

Alexander I. Spira, MD, PhD, FACP, highlights several unanswered questions within the KRAS G12C–positive non–small cell lung cancer space.

In an interview with CancerNetwork®, Alexander I. Spira, MD, PhD, FACP, director of the Thoracic and Phase I Programs as well as co-director of the Virginia Cancer Specialists Research Institution and clinical assistant professor at Johns Hopkin University, discussed future research efforts related to KRAS G12C–positive non–small cell lung cancer. He spoke about the necessity of assessing KRAS inhibitor plus immunotherapy combinations, resistance mechanisms, and drugs targeting other KRAS mutations.

His words are especially poignant following presentations at the 2022 World Conference on Lung Cancer, where several presentations surrounding KRAS G12C­–targeted therapies, alone and in combination, were presented, such as:

Transcript:

KRAS G12C [targeted drugs are] good, but not great. These drugs work, but everybody is looking at [mechanisms] to overcome resistance. There are new compounds [such as those targeting] SHP2 and SOS1 combined with immunotherapy [that may] improve on this. We all think about, as with all other targeted therapies, whether there will be a new generation of drugs that act even better. Most importantly, these are just [targeting] KRAS G12C. It’s the most common [KRAS mutation], but it still [represents a minority of patients with KRAS mutations overall]. What do we do about all the other KRAS mutations?

You can’t treat a target if you don’t test for the target. As a reminder to everybody, please test all patients. I get full next-generation sequencing panels and blood-based panels; it’s the most important thing.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,
Ankit Bharat, MBBS, a thoracic surgeon, discussed potential treatment emergent adverse effects or complications, as well as strategies for managing them.
Thoracic surgeon, Ankit Bharat, MBBS, discussed surgical strategies among patients with advanced lung cancer diagnoses based on staging.
2 experts in this video
2 experts in this video
Related Content